Ocaliva Lawsuit
Ocaliva lawsuits claim the drug used to treat primary biliary cholangitis (PBC) may cause serious liver injuries, including liver transplants and death. The drug was withdrawn from the market in 2025. Those injured after taking Ocaliva may qualify to file a lawsuit for compensation.
How To Qualify for an Ocaliva Liver Injury Lawsuit
To qualify for an Ocaliva liver injury lawsuit, you must have experienced specific injuries after taking Ocaliva (obeticholic acid) for primary biliary cholangitis (PBC).
We’ve provided a general example of Ocaliva lawsuit criteria. Even if you don’t think you qualify, you should contact a licensed product liability lawyer to find out about your legal options.
- Prescribed and took Ocaliva for primary biliary cholangitis (PBC)
- Developed serious liver injury, liver failure or required a liver transplant after taking Ocaliva
- A loved one died from Ocaliva liver injuries or liver transplant complications
- Diagnosis of worsening liver function occurred after starting Ocaliva
- Medical records or prescribing history document Ocaliva use and liver complications
- Not have a previous history of cirrhosis or other serious liver injury prior to taking Ocaliva
Each state has a statute of limitations, or a time limit, to file an Ocaliva lawsuit. Make sure to contact a lawyer to find out the time limits for your case and preserve your right to file a claim.
Latest Ocaliva Lawsuit and Investigation Updates
Ocaliva lawsuits are still in the early stages, and lawyers are investigating liver injury claims on behalf of individuals and families who lost loved ones because of Ocaliva liver injuries. There haven’t been any settlements or jury verdicts in Ocaliva litigation.
-
Nov. 24, 2025 – Ocaliva Withdrawn From U.S. Market
The FDA requested that Intercept withdraw Ocaliva from the market because of an excess of liver transplants and deaths in people taking the drug.
-
Dec. 12, 2024 – Patients Without Cirrhosis Suffer Serious Liver Injury
Previously, the FDA warned that Ocaliva liver injury could occur in patients with cirrhosis. The new warning found liver injury in patients without cirrhosis who took Ocaliva. Some of these cases led to transplants and death.
-
May 26, 2021 – FDA Restricted Ocaliva in Patients With Advanced Cirrhosis
Reports of liver failure, transplant and death prompted the FDA to restrict Ocaliva use in people with advanced cirrhosis.
-
Feb. 1, 2018 – Boxed Warning Added for Correct Dosing
Ocaliva’s updated label added a boxed warning for the correct dosing in people with liver impairment.
-
Sept. 21, 2017 – FDA Communication for Liver Injury, Incorrect Dosing
FDA warned that incorrect Ocaliva doses were given to some patients with impaired liver function, resulting in liver injury and death.
So far, there is no motion to consolidate Ocaliva lawsuits into a multidistrict litigation (MDL). However, if case numbers grow, plaintiffs’ attorneys may consider it.
Ocaliva Liver Injury and Withdrawal From the Market
The FDA withdrew Ocaliva from the market on Nov. 24, 2025, because it found the drug didn’t provide enough of a clinical benefit and too many patients suffered liver injuries. These serious injuries included liver transplants and death.
Prior to withdrawing the drug from the market, the FDA released several liver injury warnings and made label changes from 2017 through 2024.
Lawsuits claim that Intercept didn’t make adequate Ocaliva label changes to warn the public about serious liver injuries and that the manufacturer continued to promote the drug despite the FDA safety communications.
Types of Ocaliva Liver Injury Lawsuits
People harmed by Ocaliva may bring different kinds of product liability claims depending on the nature of their liver injury and what the manufacturer allegedly failed to disclose.
- Bloody or black stools
- Chronic or severe belly pain
- Chronic or severe fever and chills
- Chronic or severe lightheadedness
- Chronic or severe loss of appetite or weight loss
- Chronic or severe nausea, vomiting, or diarrhea
- Chronic or severe weakness
- Coughing up or vomiting blood
- Less frequent urination
- Mental status changes such as confusion, slurred speech, mood swings, personality changes, increased sleepiness or difficulty waking up
- New or worsening tiredness
- Swollen belly
- Yellow eyes or skin
You may have suffered other signs or symptoms that aren’t listed here. If you are concerned about your health after taking Ocaliva, make sure to see your doctor.
Ocaliva Liver Failure Lawsuits
Lawsuits in this group typically involve patients who were hospitalized for acute or worsening chronic liver failure after taking Ocaliva. These people often required emergency care, intensive monitoring and aggressive treatment to stabilize their condition.
Claims may argue that the manufacturer did not adequately warn that Ocaliva could trigger serious liver injury, especially in people with underlying disease who were already vulnerable to decompensation (failing liver function).
Many of these cases also highlight long-term complications and lifestyle changes, including inability to work, lower quality of life and the emotional impact of living with progressive liver disease.
Liver Transplant and Wrongful Death Claims
More severe Ocaliva liver injury lawsuits involve patients who progressed to end-stage liver failure and needed a liver transplant after using the drug. These claims often allege catastrophic financial losses, ongoing transplant treatment, reduced life expectancy and profound impacts on daily life and family responsibilities.
Families may also pursue wrongful death lawsuits when a loved one dies from liver or transplant complications. These cases may claim loss of income, medical and funeral expenses, and the loss of companionship and support.
Not every injury will fit neatly into “liver failure” or “transplant/wrongful death,” and anyone who believes Ocaliva harmed their liver should still speak with a lawyer to see how their specific circumstances might qualify.
Ocaliva Liver Injury Studies and Safety Evidence
Ocaliva’s safety record includes multiple liver injury communications and warnings made by the FDA since 2017. These reports all warn of serious risks of liver injury, hepatic decompensation (worsening liver function) and liver failure.
In addition, a 2021 study in Hepatology Communications found that people with cirrhosis who took Ocaliva had a 3.9-fold increased risk of hepatic decompensation compared to people with cirrhosis who did not take Ocaliva.
Ultimately, the FDA found the risk of liver injuries too great to keep Ocaliva on the market.
Choosing an Ocaliva Lawyer
Choosing an experienced Ocaliva lawyer can make the litigation process less stressful and help protect your rights at every stage of a potential claim. Firms that routinely handle drug and device litigation understand the medical issues, the FDA regulatory background and the tactics large manufacturers use to fight these cases.
An Ocaliva lawyer can review your medical records, pharmacy history and timeline of Ocaliva use to see whether your liver problems may be linked to the drug. They will also prepare and file all legal paperwork, handle negotiations with the drug manufacturer or its insurers and take the case to trial if a fair settlement is not offered.
Many pharmaceutical injury law firms offer free case reviews, so you can find out whether you may qualify for an Ocaliva lawsuit without any upfront cost. These firms often work on a contingency fee basis, meaning you generally do not pay attorney fees unless they recover compensation through a settlement or verdict.
The information on this page is meant to be a guide, not legal advice. For help filing a claim, request a free, no-obligation case review through Consumer Notice. We’ll match you with an experienced, vetted Ocaliva lawyer.
4 Cited Research Articles
Consumernotice.org adheres to the highest ethical standards for content production and references only credible sources of information, including government reports, interviews with experts, highly regarded nonprofit organizations, peer-reviewed journals, court records and academic organizations. You can learn more about our dedication to relevance, accuracy and transparency by reading our editorial policy.
- Zeta, L.M. (2025, November 24). Intercept Pharmaceuticals, Inc., et al.; Withdrawal of Approval of New Drug Application for OCALIVA (Obeticholic Acid) Tablets, 5 Milligrams and 10 Milligrams, and Three Abbreviated New Drug Applications for Obeticholic Acid Tablets, 5 Milligrams and 10 Milligrams. Retrieved from https://www.federalregister.gov/documents/2025/11/24/2025-20767/intercept-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-new-drug-application-for-ocaliva
- U.S. Food and Drug Administration. (2024, December 30). Serious Liver Injury Being Observed in Patients Without Cirrhosis Taking Ocaliva (Obeticholic Acid) To Treat Primary Biliary Cholangitis. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/serious-liver-injury-being-observed-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-treat
- John, B.V. et al. (2021, May 6). Impact of Obeticholic Acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8369937/
- U.S. Food and Drug Administration. (2018, February 5). FDA Drug Safety Communication: FDA Warns About Serious Liver Injury With Ocaliva (Obeticholic Acid) For Rare Chronic Liver Disease. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-liver-injury-ocaliva-obeticholic-acid-rare
Calling this number connects you with a Consumer Notice, LLC representative. We will direct you to one of our trusted legal partners for a free case review.
Consumer Notice, LLC's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.
844-420-1914